Compare · CTCX vs DXCM
CTCX vs DXCM
Side-by-side comparison of Carmell Corporation (CTCX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTCX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $33.65B.
- DXCM has hit the wire 9 times in the past 4 weeks while CTCX has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for CTCX).
- Company
- Carmell Corporation
- DexCom Inc.
- Price
- -
- -
- Market cap
- -
- $33.65B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CTCX
- SEC Form 424B3 filed by Carmell Corporation
- Carmell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 424B3 filed by Carmell Corporation
- Carmell Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY
- SEC Form 424B3 filed by Carmell Corporation
- Carmell Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 424B3 filed by Carmell Corporation
- SEC Form EFFECT filed by Carmell Corporation
- SEC Form DEF 14A filed by Carmell Corporation
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)
- EVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)
- President, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax
- EVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)
- Executive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)
- EVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)
- Director Augustinos Nicholas gifted 1,075 shares (SEC Form 4)
- Director Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)
- Director Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by DexCom Inc.